Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8613
Authors: Foerster, Friedrich
Gairing, Simon Johannes
Ilyas, Sumera Irie
Galle, Peter R.
Title: Emerging immunotherapy for HCC : a guide for hepatologists
Online publication date: 19-Jan-2023
Year of first publication: 2022
Language: english
Abstract: HCC is one of the most common cancers worldwide, and the third leading cause of cancer-related death globally. HCC comprises nearly 90% of all cases of primary liver cancer. Approximately half of all patients with HCC receive systemic therapy during their disease course, particularly in the advanced stages of disease. Immuno-oncology has been paradigm shifting for the treatment of human cancers, with strong and durable antitumor activity in a subset of patients across a variety of malignancies including HCC. Immune checkpoint inhibition with atezolizumab and bevacizumab, an antivascular endothelial growth factor neutralizing antibody, has become first-line therapy for patients with advanced HCC. Beyond immune checkpoint inhibition, immunotherapeutic strategies such as oncolytic viroimmunotherapy and adoptive T-cell transfer are currently under investigation. The tumor immune microenvironment of HCC has significant immunosuppressive elements that may affect response to immunotherapy. Major unmet challenges include defining the role of immunotherapy in earlier stages of HCC, evaluating combinatorial strategies that use targeting of the immune microenvironment plus immune checkpoint inhibition, and identifying treatment strategies for patients who do not respond to the currently available immunotherapies. Herein, we review the rationale, mechanistic basis and supporting preclinical evidence, and available clinical evidence for immunotherapies in HCC as well as ongoing clinical trials of immunotherapy.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-8613
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY-NC
Information on rights of use: https://creativecommons.org/licenses/by-nc/4.0/
Journal: Hepatology
75
6
Pages or article number: 1604
1626
Publisher: Wiley Interscience
Publisher place: New York, NY u.a.
Issue date: 2022
ISSN: 1527-3350
Publisher DOI: 10.1002/hep.32447
Appears in collections:DFG-491381577-H

Files in This Item:
  File Description SizeFormat
Thumbnail
emerging_immunotherapy_for_hc-20230119115733564.pdf1.51 MBAdobe PDFView/Open